What is CATX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.30B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CATX?

P/E (TTM) is n/a and 52-week range is $1.96 to $6.16 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CATX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CATX?

The company profile lists revenue (TTM) near $388K, net income (TTM) near $-11.04B, EPS (TTM) near $-1.33 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Perspective Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Seattle, Washington, US, 114M shares outstanding, ISIN US46489V3024 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Perspective Therapeutics Inc

$CATX

Health Care · Biotechnology

IR Run Scenarios

$2.66

-1.84%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company is headquartered in Seattle, Washington and currently employs 163 full-time employees. The company went IPO on 2002-05-31. The firm has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The company is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The firm's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. The company has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.

Employees

165

Website

www.perspectivetherapeutics.com/

IPO

2002-05-31

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)